Insmed stock falls 6.39 percent after CFO exit announcement
Published on 10/05/2026 at 20:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Insmed stock (ISIN US4576693075) was trading at USD 104.02 on Nasdaq on October 5, 2026 at 2:10 p.m. ET, down 6.39 percent from USD 111.12. The decline followed the company's announcement that CFO Sara Bonstein will step down on October 30, 2026, while Insmed keeps its 2026 revenue outlook unchanged, according to Insmed Incorporated on October 5, 2026.
CFO transition meets firm guidance
Bonstein will remain in the role through the company's third-quarter reporting process and participate in the earnings call scheduled for October 29, 2026. Insmed said the departure is unrelated to disagreements over accounting practices, financial statements, internal controls or operations, while the search for a successor is underway, according to Insmed Incorporated.
The company reaffirmed BRINSUPRI revenue guidance of USD 1.25 billion to USD 1.40 billion for fiscal year 2026 and ARIKAYCE guidance of USD 450 million to USD 470 million, keeping the commercial outlook intact despite the management change.
Q2 growth meets a loss
Insmed's second-quarter 2026 revenue reached USD 425.49 million, up 296.1 percent from the same quarter a year earlier. According to MarketBeat, the company reported adjusted EPS of negative USD 0.06 versus a consensus loss of USD 0.67, while revenue exceeded the USD 395.50 million estimate by USD 29.99 million.
The result shows the split in the current investment case: product sales are scaling rapidly, but Insmed remains loss-making. Standardized second-quarter data show consolidated net income of negative USD 13.242 million and operating cash flow of negative USD 88.828 million for the period ended June 30, 2026.
Consensus target stays above price
MarketBeat lists a Buy consensus from 25 analysts and an average price target of USD 200.57. That target lies 92.8 percent above the USD 104.02 Nasdaq price, a wide gap that leaves the October 5 selloff focused on execution and leadership continuity rather than a reduced revenue forecast, according to MarketBeat.
Nasdaq range sets the risk frame
INSM's October 5 session range was USD 101.72 to USD 108.75, with the stock at USD 104.02 during trading. The 52-week range of USD 90.39 to USD 212.75 places the share price 51.1 percent below its yearly high, while market capitalization stood at USD 22.5 billion on October 5, 2026.
Stock trades below yearly high
Insmed stock was last at USD 104.02 on Nasdaq on October 5, 2026 at 2:10 p.m. ET, with a 6.39 percent daily decline and a USD 212.75 52-week high.
Insmed stock key facts
- Company: Insmed Incorporated
- ISIN: US4576693075
- Ticker: INSM
- Trading venue: Nasdaq
- Price (as of October 5, 2026, 2:10 p.m. ET): USD 104.02
- Market capitalization: USD 22.5 billion (as of October 5, 2026)
- 52-week range: USD 90.39-212.75 (as of October 5, 2026)
- Sector / Industry: Health Care / Biotechnology
Upcoming dates for Insmed stock
- October 29, 2026: Third-quarter 2026 financial results and conference call
- October 30, 2026: Sara Bonstein steps down as CFO
